MORAVIAN-CHURCH-STTLMNTS
26.7.2024 11:15:27 CEST | Business Wire | Press release
Today, J. William Reynolds, Mayor of the City of Bethlehem, and Chair of the Bethlehem World Heritage Commission — speaking on behalf of all four historic Moravian communities — announced that Moravian Church Settlements has been inscribed on the prestigious World Heritage List at the World Heritage Committee meeting in New Delhi, India, July 21-31, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726407698/en/
Moravian Church Settlements Delegation at the World Heritage Committee meeting. Pictured here (from left) are Jean Manes, U.S. Deputy Representative to UNESCO; Moravian University President Bryon L. Grigsby; Bethlehem Mayor J. William Reynolds; Johnathan Putnam, Acting Chief, Office of International Affairs National Park Service; Rt. Rev. Chris Giesler; Mr. Clemens, Saxon State Minister of the Chancellery (Photo: Business Wire)
The historic Moravian Church Settlements of Bethlehem, Pennsylvania/USA; Gracehill, Northern Ireland/UK; and Herrnhut, Germany now join Christiansfeld, Denmark (already inscribed in 2015) as a single World Heritage site that represents the outstanding universal value of these historic settlements and the worldwide influence of the Moravian Church.
“We would like to express our appreciation to our respective governments of the United States, Denmark, Germany, and Northern Ireland/UK for their efforts on behalf of Moravian Church Settlements,” said Mayor Reynolds.
More information can be found on moravianchurchsettlements.org, launching today.
Moravian Church Settlements is a transnational extension of Christiansfeld, a Moravian Church Settlement in Denmark founded in 1773 and inscribed on the World Heritage List in 2015. The Moravian Church is a Protestant denomination in the free church tradition centered in Herrnhut, Saxony, Germany. The extension includes three additional component parts:
Bethlehem (USA) was established in the Commonwealth of Pennsylvania in 1741. This highlights the early transatlantic dimension of the Moravian Church phenomenon during a prolific settlement-building decade and added the cultural dimension of the Moravians’ outreach to Native Americans.
Gracehill (UK) was founded in Northern Ireland in 1759. It represents the significance of the Moravian Church in the UK and exemplifies a unique series of ‘ideal’ urban plans that demonstrate a notable gender axis. This is showcased by the division of the town plan into a sisters’ side and a brothers’ side, which directly reflects the fundamental functional structure of Moravian society.
Herrnhut (Germany) is considered the ‘mother’ or ‘founding town’ of the Renewed Moravian Church. It was established in 1722 in Saxony and evolved in line with the development of Moravian theology and societal ideals. This town defined the principles of all Moravian Church settlements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240726407698/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom